Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

May 1, 2026 09:10 AM EDT R&D Sum­mit slips on ivonescimab's ap­par­ent in­ter­im miss in sign of in­vestor frus­tra­tion Max Gelman Senior Editor Sum­mit Ther­a­peu­tics’ stock price $SMMT tum­bled near­ly 20% af­ter the clos­ing bell Thurs­day af­ter­noon, fol­low­ing an ap­par­ent sta­tis­ti­cal miss in part of a Phase 3 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER